Revaprazan
Revaprazan (SB 641257) is reversible proton pump inhibitor. Revaprazan can inhibit gastric acid secretion and protect gastric mucosa. Revaprazan can inhibit IkappaB-alpha degradation as well as Akt inactivation, resulting in attenuation of H. pylori-induced COX-2 expression. Revaprazan can be used for the researches of infection and inflammmation, such as H. pylori-infected gastric inflammation and gastric ulcer[1][2].
Product Specifications
CAS Number
199463-33-7
Product Name Alternative
SB 641257
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Akt; Bacterial; COX; ERK; NF-κB; Proton Pump
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/revaprazan.html
Solubility
10 mM in DMSO
Smiles
CC1=C(C)C(N2C(C)C3=C(C=CC=C3)CC2)=NC(NC4=CC=C(F)C=C4)=N1
Molecular Formula
C22H23FN4
Molecular Weight
362.44
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
COX-2
Citation 01
Pharmaceuticals (Basel) . 2022 Sep 25;15 (10) :1186.|BMC Microbiol. 2025 Nov 5;25 (1) :715.
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Rb1 (Tumor Suppressor Protein) (RB1/1754), CF488A conjugate, 0.1mg/mL
Recombinant Bifidobacterium longum Probable endonuclease 4 (nfo)
Recombinant Bifidobacterium longum Probable endonuclease 4 (nfo)
Recombinant Bifidobacterium longum Probable endonuclease 4 (nfo)